Our Take
NICE approval clears NHS funding for a narrow population (prior triptan failure required), not a breakthrough in migraine science but a meaningful access win for patients who've exhausted first-line options.
Why it matters
Migraine affects 10 million UK adults and costs the economy £8.8 billion annually in lost productivity. Treatment access has been fragmented across regions; NICE guidance creates a standardised pathway for eligible patients and removes funding ambiguity for NHS commissioners.
Do this week
NHS migraine clinics: audit your current triptan failure cohort to identify eligible candidates for Aquipta referral before local formulary committees complete implementation (typically 3–6 months post-NICE guidance).
NICE greenlights Aquipta for refractory acute migraine
The National Institute for Health and Care Excellence (NICE) has recommended AbbVie's atogepant (Aquipta) as a treatment option for acute migraine in adults across England and Wales. The guidance follows UK Medicines and Healthcare products Regulatory Agency (MHRA) marketing authorisation in April 2026.
Aquipta is positioned for a specific patient cohort: adults who have tried at least two triptans without adequate response or tolerability, and who have also had insufficient response to NSAIDs and paracetamol. Eligible patients will gain NHS access to the oral treatment.
The recommendation rests on phase 3 data from the Eclipse trial. In that study, 24.3% of patients receiving atogepant achieved pain freedom at two hours post-dose during the first migraine attack, versus 13.1% for placebo (company-reported).
Access and clinical clarity, not efficacy surprise
NICE approval does two things. First, it signals to NHS England and NHS Wales that the treatment meets the cost-effectiveness threshold for public funding. Second, it provides clinicians with explicit guidance on patient selection, reducing postcode variability in prescribing.
Migraine affects approximately 10 million adults in the UK and carries an estimated annual economic cost of £8.8 billion in lost productivity (per the Migraine Trust). Access to appropriate care has been inconsistent across regions, with patients often waiting months to see specialists or cycling through multiple medications before finding one that works.
Rob Music, CEO of the Migraine Trust, noted the importance of guideline clarity: "Access to appropriate care for people with migraine can be seriously inconsistent, creating a postcode lottery." NICE guidance removes one source of that lottery by establishing a shared clinical pathway.
The narrow population (prior treatment failure required) means Aquipta will not address the broader migraine population. It sits downstream of standard care, not at the front line. That is by design: the recommendation reflects both the evidence and the NHS's typical cost-control approach for specialist medications.
What NHS migraine services should do now
Formulary committees and migraine clinics should begin identifying patients currently cycling through triptans and other first-line agents without sufficient benefit. NICE guidance typically translates into local NHS policy within 3–6 months; early case identification will smooth transition to Aquipta prescribing once funding approval is codified in commissioning plans.
Clinicians should familiarise themselves with the eligibility criteria: prior triptan trial (minimum two agents) with inadequate response or intolerance, plus failed NSAID and paracetamol trials. The Phase 3 trial efficacy (24.3% pain freedom at two hours) should set expectations; this is a treatment option for a defined subpopulation, not a universal migraine solution.